- Home
- TPB vs RARE Comparison
TPB vs RARE Comparison
Compare TPB & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPB | RARE |
|---|---|---|
| Founded | 1988 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Tobacco | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 2015 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TPB | RARE |
|---|---|---|
| Price | $87.09 | $18.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 18 |
| Target Price | ★ $115.00 | $61.22 |
| AVG Volume (30 Days) | 459.0K | ★ 1.6M |
| Earning Date | 03-02-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | ★ 45.33 | 7.31 |
| EPS | ★ 3.11 | N/A |
| Revenue | $463,062,000.00 | ★ $673,000,000.00 |
| Revenue This Year | $12.04 | $13.40 |
| Revenue Next Year | $15.13 | $42.83 |
| P/E Ratio | $27.23 | ★ N/A |
| Revenue Growth | ★ 28.39 | 20.13 |
| 52 Week Low | $51.48 | $18.41 |
| 52 Week High | $146.90 | $40.17 |
Technical Indicators
Market Signals| Indicator | TPB | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 28.22 | 30.10 |
| Support Level | $82.93 | $18.41 |
| Resistance Level | $103.76 | $23.44 |
| Average True Range (ATR) | 3.80 | 0.81 |
| MACD | -0.56 | -0.20 |
| Stochastic Oscillator | 28.08 | 8.14 |
Price Performance
Historical ComparisonAbout TPB Turning Point Brands Inc.
Turning Point Brands Inc operates as manufacturer, marketer, provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in two segments namely Zig-Zag products and Stoker's products segment. The company generates maximum revenue from the Zig-Zag products segment.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.